Takhzyro 300 mg/2 mL (150 mg/mL) prefilled syringe Images
Generic Name: lanadelumab
This medication has been identified as Takhzyro 300 mg/2 mL (150 mg/mL) prefilled syringe. It is supplied by Takeda Pharmaceutical Company Limited.
Takhzyro is used in the treatment of Hereditary Angioedema and belongs to the drug class hereditary angioedema agents. Takhzyro 300 mg/2 mL (150 mg/mL) prefilled syringe is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication
Takhzyro
- Generic Name
- lanadelumab
- Strength
- 300 mg/2 mL (150 mg/mL) prefilled syringe
- Availability
- Prescription only
- Drug Class
- Hereditary angioedema agents
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Takeda Pharmaceutical Company Limited
- National Drug Code (NDC)
- 47783-0646
See also:
Berinert
Berinert is used to treat acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks ...
Kalbitor
Kalbitor is used to treat acute attacks of hereditary angioedema (HAE) in patients 12 years and ...
Orladeyo
Orladeyo (berotralstat) is used to prevent attacks of hereditary angioedema (HAE). Includes ...
Haegarda
Haegarda is an injectable protein replacement therapy that prevents swelling and attacks in ...
Firazyr
Firazyr is used to treat acute attacks of hereditary angioedema (HAE) in adults. It can be ...
Cinryze
Cinryze (complement C1 esterase inhibitor) is used to prevent attacks of angioedema in people with ...
More about Takhzyro (lanadelumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: hereditary angioedema agents
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.